0000012208-23-000058.txt : 20230720 0000012208-23-000058.hdr.sgml : 20230720 20230720163117 ACCESSION NUMBER: 0000012208-23-000058 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230720 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 231100205 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 bio-20230720.htm 8-K bio-20230720
0000012208false00000122082023-07-202023-07-200000012208us-gaap:CommonClassAMember2023-07-202023-07-200000012208us-gaap:CommonClassBMember2023-07-202023-07-20


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:   July 20, 2023
(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928
 
Delaware 94-1381833
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
 
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
 
(510)724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐




ITEM 8.01    Other Events.

On July 20, 2023, Bio-Rad Laboratories, Inc. (the “Company”) announced that its board of directors authorized a new share repurchase program (“New Share Repurchase Program”) granting the Company authority to repurchase, on a discretionary basis, up to $500 million of the outstanding shares of the Company’s common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The New Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions and minimizing dilution from stock issuances. The Company previously announced on June 5, 2023 that it had completed the repurchase of the aggregate of $650 million of stock authorized under the prior share repurchase program approved by the Company’s board of directors in November 2017, July 2020, and July 2022 (“Prior Share Repurchase Program”.) The New Share Repurchase Program supersedes the Company’s Prior Share Repurchase Program.

A copy of the press release announcing this action is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


ITEM 9.01    Financial Statements and Exhibits
Exhibit
Number 		 Description
99.1  
104.1Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document







SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
  BIO-RAD LABORATORIES, INC.
   
Date:July 20, 2023By:/s/ Timothy S. Ernst
   Timothy S. Ernst
   Executive Vice President, General Counsel and Secretary


 EX-99.1 2 pressreleasedatedjuly202023.htm EX-99.1 Document

Exhibit 99.1
Press Release

Bio-Rad Announces New Share Repurchase Program

HERCULES, Calif. — July 20, 2023 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.
 
“The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as part of our capital allocation strategy." said Norman Schwartz, Bio-Rad’s Chief Executive Officer.
 
The Company previously announced on June 5, 2023, that it had completed the repurchase of all of its common stock authorized under the prior share repurchase program approved by the Company’s board of directors.
 
Repurchases under the new share repurchase program may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The new share repurchase program has no time limit and may be suspended or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution from stock issuances.
 
About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,300 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
 
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our new share repurchase program and our continued commitment to using this tool as part of our capital allocation strategy. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements are based on assumptions and expectations of future events that are subject to risks and uncertainties, which could cause actual results to vary materially from the plans, goals, and expectations expressed in or indicated by the forward-looking statements. These risks and uncertainties include the



impact of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, global economic and geopolitical conditions, reductions in government funding and the capital spending programs of our customers, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements. 

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com
Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
pr@bio-rad.com



 EX-101.SCH 3 bio-20230720.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bio-20230720_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bio-20230720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Class B [Member] Common Class B [Member] Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Written Communications Written Communications Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Common Class A [Member] Common Class A [Member] Document Type Document Type Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 bio-20230720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information Document
Jul. 20, 2023
Entity Information [Line Items]  
Entity Central Index Key 0000012208
Entity Emerging Growth Company false
Written Communications false
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Jul. 20, 2023
Entity Registrant Name BIO-RAD LABORATORIES, INC.
Entity File Number 1-7928
Entity Tax Identification Number 94-1381833
Entity Address, Address Line One 1000 Alfred Nobel Dr.
Entity Address, City or Town Hercules
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94547
City Area Code 510
Local Phone Number 724-7000
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
Common Class A [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share
Trading Symbol BIO
Security Exchange Name NYSE
Common Class B [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share
Trading Symbol BIOb
Security Exchange Name NYSE
XML 8 bio-20230720_htm.xml IDEA: XBRL DOCUMENT 0000012208 2023-07-20 2023-07-20 0000012208 us-gaap:CommonClassAMember 2023-07-20 2023-07-20 0000012208 us-gaap:CommonClassBMember 2023-07-20 2023-07-20 0000012208 false 8-K 2023-07-20 BIO-RAD LABORATORIES, INC. 1-7928 DE 94-1381833 1000 Alfred Nobel Dr. Hercules CA 94547 510 724-7000 false false false false Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIOb NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.bio-rad.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports bio-20230720.htm bio-20230720.xsd bio-20230720_def.xml bio-20230720_lab.xml bio-20230720_pre.xml pressreleasedatedjuly202023.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bio-20230720.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bio-20230720_def.xml" ] }, "inline": { "local": [ "bio-20230720.htm" ] }, "labelLink": { "local": [ "bio-20230720_lab.xml" ] }, "presentationLink": { "local": [ "bio-20230720_pre.xml" ] }, "schema": { "local": [ "bio-20230720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 2, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20230720", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20230720.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityEmergingGrowthCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information Document", "menuCat": "Cover", "order": "1", "role": "http://www.bio-rad.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bio-20230720.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityEmergingGrowthCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bio_DocumentandEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]", "terseLabel": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentandEntityInformationAbstract", "nsuri": "http://www.bio-rad.com/20230720", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000012208-23-000058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-23-000058-xbrl.zip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end